TY - JOUR
T1 - Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer
AU - Kitagawa, Chiyoe
AU - Iwasaku, Masahiro
AU - Kogure, Yoshihito
AU - Ando, Masahiko
AU - Yoshioka, Hiroshige
AU - Nishiyama, Akihiro
AU - Watanabe, Naoki
AU - Kunimasa, Kei
AU - Tsubouchi, Kazuya
AU - Oka, Saori
AU - Saka, Hideo
N1 - Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.
AB - Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.
UR - http://www.scopus.com/inward/record.url?scp=85059225879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059225879&partnerID=8YFLogxK
U2 - 10.21873/invivo.11453
DO - 10.21873/invivo.11453
M3 - Article
C2 - 30587617
AN - SCOPUS:85059225879
SN - 0258-851X
VL - 33
SP - 163
EP - 166
JO - In Vivo
JF - In Vivo
IS - 1
ER -
